News

Proceeds from the financing will be used to accelerate development of Atrimers, a new class of protein therapeutics that the company is developing to address significant unmet medical

His resignation, effective January 9, 2009, follows an 11-year career with Acusphere, in which he oversaw the company’s clinical trials for its lead product candidate, Imagify for injectable

Numoda is currently managing Columbia’s ongoing Pregnant study of Prochieve 8% (progesterone gel) to reduce the risk of preterm birth in women with a short cervix at mid-pregnancy.

KMD-3213 is a selective alpha 1A-adrenoceptor antagonist originally discovered by Kissei Pharmaceutical Co. It was developed by Daiichi Sankyo and Kissei Pharmaceutical and is jointly marketed as Urief

Mr Howard joins MDS Pharma Services from his private consulting practice where he offered business and financial consulting services, including merger and acquisition services, for clients across a

Under the agreement, Teva would be using the Codexis process for key process steps in the manufacture of this product, assuming technical milestones are met. Financial terms were

“This is yet another important step in Rosetta Genomics’ commercialization efforts,” noted Ronen Tamir, Chief Commercialization Officer at Rosetta Genomics. “As Israel provided its citizens with health insurance

Ms Grahn was most recently vice president of clinical operations at MedGenesis Therapeutix. At Horizon, Ms Grahn will lead all clinical operations activities. Ms Grahn has a master’s

Mr McCoy will continue to serve on the board as a director. Mr Edgerton has served on the company’s board of directors since February 2007. Mr Edgerton spent